Name: Liraglutide Standard
SKU: LS-4051
Availability: InStock

Grouped product items

Cantidad

Unidad de venta

Precio

Unidad de almacenamiento de stock (SKU)

2,5 mg

A petición

LS-4051.0000

Hoja de seguridad

description

20mg per vial net peptide content, as peptide standard for quantitative analysis. Glucagon-Like-Peptide-1 (GLP-1) agonist used for the treatment of type 2 diabetes. It is an incretin mimetic stimulating the release and synthesis of insulin into the blood by the intestine in response to food. It is only active in the presence of high circulating glucose levels. It also slows the passage of food through the gut and reduces appetite.

references

Innovative chemical synthesis and conformational hints on the lipopeptide liraglutide; I. Guryanov, A. Bondesan, D. Visentini, A. Orlandin, B. Biondi, C. Toniolo, F. Formaggio, A. Ricci, J. Zanon and W. Cabri; J Pept Sci 2016; 22: 471-9. https://doi.org/10.1002/psc.2890

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide; J. Lau, P. Bloch, L. Schäffer, I. Pettersson, J. Spetzler, J. Kofoed, K. Madsen, L. B. Knudsen, J. McGuire, D. B. Steensgaard, H. M. Strauss, D. X. Gram, S. M. Knudsen, F. S. Nielsen, P. Thygesen, S. Reedtz-Runge and T. Kruse; Journal of medicinal chemistry 2015; 58: 7370-7380. https://doi.org/10.1021/acs.jmedchem.5b00726

The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates; C. F. Gotfredsen, A. M. Molck, I. Thorup, N. C. Nyborg, Z. Salanti, L. B. Knudsen and M. O. Larsen; Diabetes 2014; 63: 2486-97. https://doi.org/10.2337/db13-1087

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors; J. J. Neumiller; J Am Pharm Assoc (2003) 2009; 49 Suppl 1: S16-29. https://doi.org/10.1331/JAPhA.2009.09078

Liraglutide in type 2 diabetes: from pharmacological development to clinical practice; M. C. Rossi and A. Nicolucci; Acta Biomed 2009; 80: 93-101.

Potential of liraglutide in the treatment of patients with type 2 diabetes; C. F. Deacon; Vasc Health Risk Manag 2009; 5: 199-211. https://doi.org/10.2147/vhrm.s4039